Audentes Therapeutics Announces Changes to Senior Management Team

Audentes Therapeutics appointed Edward R. Conner, M.D. as Senior Vice President and Chief Medical Officer and promoted Fulvio Mavilio, Ph.D. to Senior Vice President of Translational Science. Dr. Suyash Prasad, Senior Vice President and Chief Medical Officer and Dr. John Gray, Senior Vice President and Chief Technology Officer are leaving Audentes.

"We are delighted to welcome Ed and Fulvio to our senior leadership team," said Matthew R. Patterson, Chairman and Chief Executive Officer. "Each is a recognized industry leader with a demonstrated track-record in the development of novel gene therapy products targeting rare diseases, and we look forward to their contributions as we progress AT132 for the treatment of XLMTM towards regulatory submissions, and advance our Pompe, Duchenne muscular dystrophy, and myotonic dystrophy programs into clinical development. I would also like to thank Suyash and John for their numerous important contributions to Audentes."

As Senior Vice President and Chief Medical Officer, Conner will be responsible for leading the global clinical development strategy for Audentes. He will oversee clinical development, clinical operations, regulatory affairs, medical affairs and patient advocacy. Conner's appointment is effective July 15, 2019. In Mavilio's new role as Senior Vice President of Translational Science, he is responsible for advancing the company's pipeline from discovery through to IND-enabling preclinical development. Mavilio oversees the molecular biology, in vivo pharmacology, bioinformatics and bioanalytics functions.

Conner joins Audentes from Sangamo Therapeutics where he served as Senior Vice President and Chief Medical Officer and led the clinical development of the company's pipeline of genomic therapies. Prior to Sangamo, Conner served as Vice President, Global Clinical Development at Ultragenyx Pharmaceutical where he led the global clinical development efforts for two of the company's rare disease product candidates. Prior to Ultragenyx, Ed served as Senior Medical Director at BioMarin Pharmaceutical Inc., where he led clinical development and regulatory interactions for its global Phase 3 program in Pompe disease, and earlier in his career Conner served as Medical Director at Genentech where he was the clinical science team leader of two product candidates, including XOLAIR®. Conner completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco.

Mavilio is a highly regarded, world-leading expert and pioneer in the gene therapy field. He has designed and developed gene therapies for inherited and acquired diseases, including the first ever commercially approved ex vivo gene therapy, Strimvelis®. Mavilio joined Audentes in 2017 from Genethon where he served as Chief Scientific Officer and led the development of a robust pipeline of gene therapy programs, including the initial discovery work for AT132. Prior to Genethon, Mavilio was co-Director of the Center for Regenerative Medicine of the University of Modena, Director of Discovery of Molmed SpA, founder and Chief Scientific Officer of Genera SpA, and co-Director of the San Raffaele-Telethon Institute of Gene Therapy. Mavilio serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia. He earned an undergraduate degree in Biology at the University of Rome and a Ph.D. in Medical Genetics at the University of Rome School of Medicine.

Register as Visitor to CPhI China 2019 NOW!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com.